CTNM - CIK 0001855175
Contineum Therapeutics, Inc. trades as CTNM. In its fiscal 2024 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$59.98M. This page tracks Contineum Therapeutics, Inc. through 156 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Insider sale notice | 144 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
The largest companies sharing Contineum Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Contineum Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2024, a decrease of 100.0% year over year.
In its latest fiscal year Contineum Therapeutics, Inc. reported a net loss of $59.98M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.